{"entity":{"id":"john-heymach","kind":"person","name":"John V. Heymach","aka":[],"tldr":"Lung cancer leader behind trials that changed treatment of EGFR-mutant and stage III disease.","summary":"John Heymach is Chair of Thoracic/Head and Neck Medical Oncology at MD Anderson Cancer Center. A medical oncologist and cancer biologist specialising in lung cancer, targeted therapy and immunotherapy, he was principal investigator of AEGEAN, the perioperative durvalumab trial, and leads EGFR and KRAS-directed programmes including work on osimertinib in stage III disease in the LAURA trial and on targeting drug-tolerant persister cells. His papers report perioperative durvalumab for resectable non-small-cell lung cancer in the New England Journal of Medicine and the ZODIAC phase 3 trial of vandetanib plus docetaxel as second-line treatment in advanced non-small-cell lung cancer. His work also covers small-cell lung cancer and head and neck squamous cell carcinoma.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/John_V._Heymach","links":[{"label":"MD Anderson faculty","url":"https://faculty.mdanderson.org/search?q=John%20V.%20Heymach"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Heymach%20JV%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=John%20V.%20Heymach"}],"tags":[],"related":[],"cancers":["nsclc","sclc","head-and-neck"],"sections":[],"technologies":[],"targets":["egfr","kras"],"drugs":["osimertinib","durvalumab"],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chair, Thoracic/Head and Neck Medical Oncology, MD Anderson","institutionId":"md-anderson","specialisms":["Lung cancer","Targeted therapy","Immunotherapy"],"profiles":[{"label":"MD Anderson faculty","url":"https://faculty.mdanderson.org/search?q=John%20V.%20Heymach"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Heymach%20JV%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=John%20V.%20Heymach"}],"papers":[{"title":"Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer","journal":"New England Journal of Medicine","year":2023,"url":"https://doi.org/10.1056/NEJMoa2304875","doi":"10.1056/NEJMoa2304875"},{"title":"Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial","journal":"Lancet Oncology","year":2010,"url":"https://doi.org/10.1016/S1470-2045(10)70132-7","doi":"10.1016/S1470-2045(10)70132-7"}],"orcid":"0000-0001-9068-8942"},"route":"/people/john-heymach/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"her2-mutant-nsclc","kind":"cancer","name":"HER2-mutant non-small-cell lung cancer","route":"/cancers/her2-mutant-nsclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"resectable-nsclc","kind":"cancer","name":"Resectable stage I to III non-small-cell lung cancer","route":"/cancers/resectable-nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"target":[{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/"},{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/"}],"drug":[{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/"},{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/"}],"institution":[{"id":"md-anderson","kind":"institution","name":"MD Anderson Cancer Center","route":"/institutions/md-anderson/"}],"paper":[{"id":"paper-gay-sclc-subtypes-inflamed-cancer-cell-2021","kind":"paper","name":"Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities","route":"/key-papers/paper-gay-sclc-subtypes-inflamed-cancer-cell-2021/"},{"id":"paper-heymach-aegean-perioperative-durvalumab-nejm-2023","kind":"paper","name":"Perioperative durvalumab for resectable non-small-cell lung cancer","route":"/key-papers/paper-heymach-aegean-perioperative-durvalumab-nejm-2023/"}],"trial":[{"id":"beamion-lung-1","kind":"trial","name":"Beamion LUNG-1","route":"/trials/beamion-lung-1/"}]}}